Pancreatic cancer is a type of cancer that starts in the pancreas. The pancreas is an organ that sits behind the stomach and produces enzymes to help with digestion. Pancreatic cancer can be difficult to diagnose because it often does not cause any symptoms until it has spread to other parts of the body. Pancreatic cancer is one of the most deadly cancers, with a five-year survival rate of less than 5%.
The global pancreatic cancer diagnostic market was valued at USD 1,890 million in 2018 and is projected to reach USD 2,907 million by 2030, growing at a CAGR of 6.2% from 2019-2030. Imaging segment accounted for the largest share in 2018 and will continue its dominance throughout the forecast period owing to its high accuracy rates and low cost as compared to other methods such as biopsy or tumor biomarker tests. Hospitals segment dominated this market in 2018 due to their higher number of patients diagnosed with pancreatic cancer as compared with clinics which are more focused on diagnosis rather than treatment facilities. North America dominated this market in 2018 due to higher incidence rates for pancreatic cancers as compared with other regions such as Asia Pacific or Europe owing mainly due increased awareness about early detection among people living there which will continue through 2030 when it will account for over 40% share globally.
Some Of The Growth Factors Of This Market:
- The number of people diagnosed with pancreatic cancer is increasing.
- Pancreatic cancer is difficult to diagnose because it often does not show any symptoms until it has progressed to an advanced stage.
- Pancreatic cancer treatments are expensive and have a low success rate, which can lead to financial difficulties for patients and their families.
- There are no screening tests for pancreatic cancer, so the only way to detect it early is through a CT scan or MRI scan of the abdomen, which can be costly and time-consuming for patients who may not have health insurance coverage or the ability to pay out-of-pocket costs associated with these scans on their own.
- The average age at diagnosis is 68 years old.
Industry Growth Insights published a new data on “Pancreatic Cancer Diagnostic Market”. The research report is titled “Pancreatic Cancer Diagnostic Market research by Types (Imaging, Tumor Biomarker, Biopsy, Other, Pancreatic Cancer Diagnosti), By Applications (Hospitals, Clinics, Others), By Players/Companies Roche, GE Healthcare, Siemens, BD, Philips Healthcare, Hitachi Medical, Danaher, Abbott, Canon Medical Systems, Myriad Genetics, Qiagen, Asuragen, BioMarker Strategies, Pancreatic Cancer Diagnosti”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pancreatic Cancer Diagnostic Market Research Report
By Type
Imaging, Tumor Biomarker, Biopsy, Other, Pancreatic Cancer Diagnosti
By Application
Hospitals, Clinics, Others
By Companies
Roche, GE Healthcare, Siemens, BD, Philips Healthcare, Hitachi Medical, Danaher, Abbott, Canon Medical Systems, Myriad Genetics, Qiagen, Asuragen, BioMarker Strategies, Pancreatic Cancer Diagnosti
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Pancreatic Cancer Diagnostic Market Report Segments:
The global Pancreatic Cancer Diagnostic market is segmented on the basis of:
Types
Imaging, Tumor Biomarker, Biopsy, Other, Pancreatic Cancer Diagnosti
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- GE Healthcare
- Siemens
- BD
- Philips Healthcare
- Hitachi Medical
- Danaher
- Abbott
- Canon Medical Systems
- Myriad Genetics
- Qiagen
- Asuragen
- BioMarker Strategies
- Pancreatic Cancer Diagnosti
Highlights of The Pancreatic Cancer Diagnostic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Imaging
- Tumor Biomarker
- Biopsy
- Other
- Pancreatic Cancer Diagnosti
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pancreatic Cancer Diagnostic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A pancreatic cancer diagnosis is based on a combination of symptoms and medical tests. Symptoms may include abdominal pain, weight loss, jaundice (yellowing of the skin and eyes), nausea, vomiting, diarrhea or constipation. A doctor may order blood tests to check for signs of pancreatic cancer such as an increase in levels of the hormone insulin or a change in the size or shape of your pancreas. Imaging tests such as ultrasound or CT scans may also be used to determine if there is any evidence of the disease inside your body.
Some of the major companies in the pancreatic cancer diagnostic market are Roche, GE Healthcare, Siemens, BD, Philips Healthcare, Hitachi Medical, Danaher, Abbott, Canon Medical Systems, Myriad Genetics, Qiagen, Asuragen, BioMarker Strategies, Pancreatic Cancer Diagnosti.
The pancreatic cancer diagnostic market is expected to grow at a compound annual growth rate of 6.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pancreatic Cancer Diagnostic Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pancreatic Cancer Diagnostic Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pancreatic Cancer Diagnostic Market - Supply Chain
4.5. Global Pancreatic Cancer Diagnostic Market Forecast
4.5.1. Pancreatic Cancer Diagnostic Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pancreatic Cancer Diagnostic Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pancreatic Cancer Diagnostic Market Absolute $ Opportunity
5. Global Pancreatic Cancer Diagnostic Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
5.3.1. Imaging
5.3.2. Tumor Biomarker
5.3.3. Biopsy
5.3.4. Other
5.3.5. Pancreatic Cancer Diagnosti
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pancreatic Cancer Diagnostic Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pancreatic Cancer Diagnostic Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pancreatic Cancer Diagnostic Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pancreatic Cancer Diagnostic Demand Share Forecast, 2019-2026
9. North America Pancreatic Cancer Diagnostic Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
9.7.1. Imaging
9.7.2. Tumor Biomarker
9.7.3. Biopsy
9.7.4. Other
9.7.5. Pancreatic Cancer Diagnosti
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pancreatic Cancer Diagnostic Demand Share Forecast, 2019-2026
10. Latin America Pancreatic Cancer Diagnostic Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
10.7.1. Imaging
10.7.2. Tumor Biomarker
10.7.3. Biopsy
10.7.4. Other
10.7.5. Pancreatic Cancer Diagnosti
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pancreatic Cancer Diagnostic Demand Share Forecast, 2019-2026
11. Europe Pancreatic Cancer Diagnostic Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
11.7.1. Imaging
11.7.2. Tumor Biomarker
11.7.3. Biopsy
11.7.4. Other
11.7.5. Pancreatic Cancer Diagnosti
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pancreatic Cancer Diagnostic Demand Share, 2019-2026
12. Asia Pacific Pancreatic Cancer Diagnostic Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
12.7.1. Imaging
12.7.2. Tumor Biomarker
12.7.3. Biopsy
12.7.4. Other
12.7.5. Pancreatic Cancer Diagnosti
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pancreatic Cancer Diagnostic Demand Share, 2019-2026
13. Middle East & Africa Pancreatic Cancer Diagnostic Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pancreatic Cancer Diagnostic Market Size and Volume Forecast by Type
13.7.1. Imaging
13.7.2. Tumor Biomarker
13.7.3. Biopsy
13.7.4. Other
13.7.5. Pancreatic Cancer Diagnosti
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pancreatic Cancer Diagnostic Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pancreatic Cancer Diagnostic Market: Market Share Analysis
14.2. Pancreatic Cancer Diagnostic Distributors and Customers
14.3. Pancreatic Cancer Diagnostic Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GE Healthcare
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Siemens
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BD
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Philips Healthcare
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Hitachi Medical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Danaher
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Abbott
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Canon Medical Systems
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Myriad Genetics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Qiagen
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Asuragen
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. BioMarker Strategies
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Pancreatic Cancer Diagnosti
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
